Clinical Efficacy of Alternative TNF Inhibitor and Secukinumab Between Primary Non-Responder and Secondary Non-Responder of Prior TNF Inhibitor in Ankylosing Spondylitis.

Hong-Ki MinHae-Rim KimSang-Heon LeeYeon Sik HongMoon-Young KimSung-Hwan ParkKwi Young Kang

Published in: Modern rheumatology (2022)

: Alternative TNFi showed better drug retention and clinical efficacy in AS patients experiencing previous TNFi failure, in secondary non-responder. Therefore, alterative TNFi may be a more suitable treatment for secondary non-responders.

Keyphrases

ankylosing spondylitis
rheumatoid arthritis
disease activity
end stage renal disease
newly diagnosed
prognostic factors
peritoneal dialysis
systemic lupus erythematosus
patient reported outcomes
electronic health record
smoking cessation